Physician profile
Wallette Widener
NPI 1669580262
$19,694.40
in general payments reported to CMS, 2019-2025
49 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,531 · 2022: $9,336 · 2023: $2,923 · 2024: $2,862 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,478 · Consulting Fee: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,477.82 |
| Consulting Fee | $1,350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $4,762.76 | 2021-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $4,210.98 | 2021-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $2,132.83 | 2021-2025 | |
| Genentech USA, INC. | $1,715.34 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Novartis Pharmaceuticals Corporation | $930.92 | 2021-2025 | |
| Biogen, INC. | $665.50 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Amgen INC. | $526.94 | 2021-2025 | Uplizna |
| Celgene Corporation | $463.21 | 2021-2025 | Zeposia |
| Ucb, INC. | $436.03 | 2021-2025 | Briviact, Fintepla, Rystiggo |
| Neurelis, INC. | $320.03 | 2021-2024 | Valtoco |
| Mallinckrodt Hospital Products INC. | $298.76 | 2021-2024 | Acthar |
| Lundbeck LLC | $254.47 | 2021-2025 | Vyepti, Rexulti |
| Horizon Therapeutics Plc | $217.92 | 2021-2023 | Uplizna |
| Jazz Pharmaceuticals INC. | $213.60 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $173.40 | 2021-2025 | Austedo Xr, Ajovy |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $172.07 | 2022-2025 | |
| Pfizer INC. | $170.59 | 2023-2025 | |
| Allergan, INC. | $170.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $134.15 | 2021-2023 | Ponvory |
| Neurocrine Biosciences, INC. | $120.44 | 2021-2024 | Ingrezza, Ongentys |
| Merz Pharmaceuticals, LLC | $103.06 | 2021-2025 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $94.55 | 2022-2025 | Dysport |
| Ani Pharmaceuticals, INC. | $93.73 | 2023 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $91.42 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $86.84 | 2021 | |
| Sk Life Science, INC. | $85.39 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $84.48 | 2022 | |
| Tanabe Pharma America, INC. | $83.23 | 2021-2025 | Radicava |
| Genentech, INC. | $78.13 | 2022 | |
| Kyowa Kirin, INC. | $75.72 | 2021-2023 | Nourianz |
| Csl Behring | $61.99 | 2021-2025 | Hizentra |
| Averitas Pharma INC. | $61.71 | 2024-2025 | Qutenza |
| Eisai INC. | $60.46 | 2021-2025 | |
| Argenx US, INC. | $56.95 | 2022-2024 | Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $56.75 | 2021-2023 | Inbrija |
| Grifols USA, LLC | $46.70 | 2023-2025 | Gamunex-C |
| Lilly USA, LLC | $45.75 | 2024-2025 | Kisunla |
| Livanova USA, INC. | $44.98 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Sarepta Therapeutics, INC. | $39.31 | 2023 | Exondys 51 |
| Acadia Pharmaceuticals INC | $36.92 | 2025 | Daybue |
| Astrazeneca Pharmaceuticals LP | $33.05 | 2024-2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $31.56 | 2021 | |
| Harmony Biosciences LLC | $31.41 | 2022 | |
| Sandoz INC. | $27.69 | 2024 | |
| Banner Life Sciences, LLC | $21.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.83 | 2024 | Hyqvia |
| Grt US Holding, INC. | $19.52 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $18.33 | 2024 | |
| Medtronic, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallette Widener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.